Business
Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment of Cancer
Jul. 21, 2011 (Canada NewsWire Group) -- TSX Venture: QPT EDMONTON, July 21, 2011 /CNW/...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n Jul. 21, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Venture: QPT\n\n\nEDMONTON, July 21, 2011 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT)\n ("Quest" or the "Company"), a pharmaceutical company developing and\n commercializing products for the treatment of cancer, today announced\n that it has received notice of allowance for U.S. Patent Application\n 10/831,886 entitled: "Combination Therapy for Treating Disease" (the\n "Patent"). The Patent covers the use of monoclonal antibodies capable\n of targeting tumor antigens CA 125, MUC1, CA 19.9, TAG-72 and prostate\n specific antigen, which are presented in ovary, breast, lung, pancreas,\n stomach and prostate cancers, respectively, in combination with a\n chemotherapeutic drug to treat cancer.\n\n\nThe Company's technology platform was based on the observation that its\n lead product, Oregovomab, when used as mono-immunotherapy during\n watchful waiting period in ovarian cancer patients was unable to meet\n progression free survival endpoint. However, when Oregovomab was\n administered in combination with front-line carboplatin-paclitaxel, the\n combination resulted in a more vigorous immune response, which in turn\n consistently correlated with favorable clinical outcome in a 40 patient\n clinical trial. An enhanced immune response was also observed with\n anti-MUC1 antibody and another chemotherapeutic agent, gemcitabine, in\n a pancreatic cancer animal model. In addition to t...